CORC

在结果中检索

CORC

浏览/检索结果: 共17条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
Rising rural body-mass index is the main driver of the global obesity epidemic in adults 期刊论文
NATURE, 2019, 卷号: 569, 期号: 7755
作者:  Regecova, Valeria;  Ye, Xingwang;  Yiallouros, Panayiotis K.;  Yngve, Agneta;  Yoosefi, Moein
收藏  |  浏览/下载：152/0  |  提交时间：2019/12/05
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression 期刊论文
2019, 卷号: 145, 期号: 6, 页码: 1569-1579
作者:  Schuler, Martin;  Tan, Eng-Huat;  O'Byrne, Kenneth;  Zhang, Li;  Boyer, Michael
收藏  |  浏览/下载：20/0  |  提交时间：2020/01/03
Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: a pooled analysis of 1018 population-based measurement studies with 88.6 million participants 期刊论文
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2018, 卷号: 47, 期号: 3
作者:  Zhou, Bin;  Bentham, James;  Di Cesare, Mariachiara;  Bixby, Honor;  Danaei, Goodarz
收藏  |  浏览/下载：81/0  |  提交时间：2019/12/05
Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults 期刊论文
LANCET, 2017, 卷号: 390, 期号: 10113
作者:  Ezzati, Majid;  Bentham, James;  Di Cesare, Mariachiara;  Bilano, Ver;  Bixby, Honor
收藏  |  浏览/下载：108/0  |  提交时间：2019/12/05
First-Line Afatinib versus Gefitinib in EGFRm plus Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7 期刊论文
2017, 卷号: 12, 期号: 1, 页码: S335-S336
作者:  Park, Keunchil;  Tan, Eng Huat;  Zhang, Li;  Hirsh, Vera;  O'Byrne, Ken
收藏  |  浏览/下载：7/0  |  提交时间：2020/01/03
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial 期刊论文
2016, 卷号: 17, 期号: 5, 页码: 577-589
作者:  Park, Keunchil;  Tan, Eng-Huat;  O'Byrne, Ken;  Zhang, Li;  Boyer, Michael
收藏  |  浏览/下载：4/0  |  提交时间：2020/01/04
First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs). 期刊论文
2016, 卷号: 34, 期号: 15
作者:  Hirsh, Vera;  Yang, James Chih-Hsin;  Tan, Eng-Huat;  O'Byrne, Ken;  Zhang, Li
收藏  |  浏览/下载：6/0  |  提交时间：2020/01/04
First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs). 会议论文
JOURNAL OF CLINICAL ONCOLOGY, 2016-05-20
作者:  Hirsh, Vera;  Yang, James Chih-Hsin;  Tan, Eng-Huat;  O'Byrne, Ken;  Zhang, Li
收藏  |  浏览/下载：7/0  |  提交时间：2020/01/04
Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis 期刊论文
2013, 卷号: 105, 期号: 9, 页码: 595-605
作者:  Lee, Chee Khoon;  Brown, Chris;  Gralla, Richard J.;  Hirsh, Vera;  Thongprasert, Sumitra
收藏  |  浏览/下载：2/0  |  提交时间：2020/01/13
Guidelines for the use and interpretation of assays for monitoring autophagy 期刊论文
AUTOPHAGY, 2012, 卷号: 8, 期号: 4, 页码: 445-544
作者:  Klionsky, Daniel J.;  Abdalla, Fabio C.;  Abeliovich, Hagai;  Abraham, Robert T.;  Acevedo-Arozena, Abraham
收藏  |  浏览/下载：190/0  |  提交时间：2018/12/29

©版权所有 ©2017 CSpace - Powered by CSpace